Aerovate Therapeutics, Inc.
AVTE
$2.66
$0.083.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.55% | 57.94% | 14.30% | 9.32% | 17.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.98% | -18.52% | 28.66% | 39.57% | 39.20% |
| Operating Income | 70.98% | 18.52% | -28.66% | -39.57% | -39.20% |
| Income Before Tax | 73.60% | 17.00% | -30.22% | -40.35% | -35.74% |
| Income Tax Expenses | -1.79% | -- | -- | -- | 124.00% |
| Earnings from Continuing Operations | 73.40% | 17.00% | -30.22% | -40.35% | -35.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.40% | 17.00% | -30.22% | -40.35% | -35.89% |
| EBIT | 70.98% | 18.52% | -28.66% | -39.57% | -39.20% |
| EBITDA | 70.98% | 19.45% | -28.66% | -39.57% | -39.20% |
| EPS Basic | 74.25% | 20.53% | -13.97% | -25.12% | -20.76% |
| Normalized Basic EPS | 74.44% | 20.52% | -13.97% | -25.10% | -20.61% |
| EPS Diluted | 74.25% | 20.53% | -13.97% | -25.12% | -20.76% |
| Normalized Diluted EPS | 74.44% | 20.52% | -13.97% | -25.10% | -20.61% |
| Average Basic Shares Outstanding | 3.31% | 4.42% | 14.26% | 12.18% | 12.53% |
| Average Diluted Shares Outstanding | 3.31% | 4.42% | 14.26% | 12.18% | 12.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
